ATE404584T1 - Peptide und peptidmimetika mit anti- proliferativer aktivität und deren verwendung - Google Patents

Peptide und peptidmimetika mit anti- proliferativer aktivität und deren verwendung

Info

Publication number
ATE404584T1
ATE404584T1 AT03729533T AT03729533T ATE404584T1 AT E404584 T1 ATE404584 T1 AT E404584T1 AT 03729533 T AT03729533 T AT 03729533T AT 03729533 T AT03729533 T AT 03729533T AT E404584 T1 ATE404584 T1 AT E404584T1
Authority
AT
Austria
Prior art keywords
peptides
peptide mimetics
proliferative activity
compounds
cell growth
Prior art date
Application number
AT03729533T
Other languages
English (en)
Inventor
Takumi Kawabe
Hidetaka Kobayashi
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Application granted granted Critical
Publication of ATE404584T1 publication Critical patent/ATE404584T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Optics & Photonics (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT03729533T 2002-01-17 2003-01-17 Peptide und peptidmimetika mit anti- proliferativer aktivität und deren verwendung ATE404584T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35020802P 2002-01-17 2002-01-17

Publications (1)

Publication Number Publication Date
ATE404584T1 true ATE404584T1 (de) 2008-08-15

Family

ID=23375680

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03729533T ATE404584T1 (de) 2002-01-17 2003-01-17 Peptide und peptidmimetika mit anti- proliferativer aktivität und deren verwendung

Country Status (18)

Country Link
US (3) US6995135B2 (de)
EP (1) EP1483290B1 (de)
JP (3) JP4041066B2 (de)
KR (2) KR100863090B1 (de)
CN (2) CN100360564C (de)
AT (1) ATE404584T1 (de)
AU (2) AU2003235576C1 (de)
CA (1) CA2471192C (de)
CY (1) CY1108470T1 (de)
DE (1) DE60322845D1 (de)
DK (1) DK1483290T3 (de)
ES (1) ES2311703T3 (de)
IL (2) IL162836A0 (de)
NO (1) NO332461B1 (de)
PT (1) PT1483290E (de)
SI (1) SI1483290T1 (de)
WO (1) WO2003059942A2 (de)
ZA (1) ZA200405455B (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1483290E (pt) * 2002-01-17 2008-09-19 Takeda Pharmaceutical Peptídeos e peptidomiméticos possuindo actividade antiproliferativa e/ou que aumentam os agentes ou tratamentos de danificação dos ácidos nucleicos
CA2487388C (en) * 2002-06-06 2011-05-10 Canbas Co., Ltd. Compounds that abrogate dna-damage-induced cell cycle g2 checkpoint and/or augment the anti-cancer activity of dna-damaging treatments
US20100210745A1 (en) * 2002-09-09 2010-08-19 Reactive Surfaces, Ltd. Molecular Healing of Polymeric Materials, Coatings, Plastics, Elastomers, Composites, Laminates, Adhesives, and Sealants by Active Enzymes
US20090238811A1 (en) * 2002-09-09 2009-09-24 Mcdaniel C Steven Enzymatic Antimicrobial and Antifouling Coatings and Polymeric Materials
US20100233146A1 (en) * 2002-09-09 2010-09-16 Reactive Surfaces, Ltd. Coatings and Surface Treatments Having Active Enzymes and Peptides
US20050058689A1 (en) * 2003-07-03 2005-03-17 Reactive Surfaces, Ltd. Antifungal paints and coatings
US20040109853A1 (en) * 2002-09-09 2004-06-10 Reactive Surfaces, Ltd. Biological active coating components, coatings, and coated surfaces
US7125842B2 (en) * 2003-04-07 2006-10-24 Canbas Co. Ltd. Anti-fungal compounds and methods of use
EP1648490A2 (de) * 2003-06-25 2006-04-26 Canbas Co., Ltd. Peptide und peptidomimetika mit immunmodulierender, entzündungshemmender und antiviraler aktivität
US8618066B1 (en) 2003-07-03 2013-12-31 Reactive Surfaces, Ltd., Llp Coating compositions having peptidic antimicrobial additives and antimicrobial additives of other configurations
WO2005014856A1 (en) * 2003-08-08 2005-02-17 Canbas Co., Ltd. Sensitivity test to predict efficacy of anti-cancer therapies
US20060286006A1 (en) * 2005-06-21 2006-12-21 Mcdaniel C S Method and apparatus for the treatment of fluid waste streams
AU2007306927B2 (en) * 2006-10-11 2013-10-03 Aushealth Corporate Pty Ltd The use of a DNA damaging agent and a ligand for the treatment of cancer
US9178387B2 (en) * 2008-05-13 2015-11-03 Qualcomm Incorporated Receive antenna for wireless power transfer
CL2009001156A1 (es) * 2008-05-14 2010-08-27 Canbas Co Ltd Acetato de un peptido de 12 aminoacidos; metodo de preparacion; composicion farmaceutica y agente que lo contiene, solo o conjuntamente con un principio activo que dana el acido nucleico; util para el tratamiento o profilaxis de trastornos proliferativos celulares.
US8388904B1 (en) 2008-12-22 2013-03-05 Reactive Surfaces, Ltd., Llp Equipment decontamination system and method
FR2942798B1 (fr) * 2009-03-05 2011-04-08 Centre Nat Rech Scient Peptides utilisables pour le traitement de la leucemie lymphoide chronique
SG179021A1 (en) * 2009-09-15 2012-04-27 Reactive Surface Ltd Anti-fouling paints and coatings
IN2014CN02398A (de) * 2011-08-31 2015-06-19 Univ New York
PT3013351T (pt) * 2013-06-24 2020-01-17 Canbas Co Ltd Péptidos e peptidomiméticos em utilizações e tratamentos combinados para subpopulações de pacientes com cancro
PT3149025T (pt) 2014-05-21 2019-08-01 Entrada Therapeutics Inc Peptídeos penetrantes de células e métodos de fabrico e utilização dos mesmos
US10815276B2 (en) 2014-05-21 2020-10-27 Entrada Therapeutics, Inc. Cell penetrating peptides and methods of making and using thereof
WO2016033368A1 (en) 2014-08-27 2016-03-03 Ohio State Innovation Foundation Improved peptidyl calcineurin inhibitors
US10149887B2 (en) * 2015-10-23 2018-12-11 Canbas Co., Ltd. Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
TWI805542B (zh) * 2015-10-23 2023-06-21 日商坎巴斯有限公司 用於癌症治療之肽及擬肽與t細胞活化劑及/或查核點抑制劑之組合
US11339192B2 (en) 2017-10-04 2022-05-24 Ohio State Innovation Foundation Bicyclic peptidyl inhibitors
EP3746105A4 (de) 2018-01-29 2022-05-18 Ohio State Innovation Foundation Zyklische peptidylinhibitoren der cal-pdz-bindenden domäne
US11576946B2 (en) 2018-01-29 2023-02-14 Ohio State Innovation Foundation Peptidyl inhibitors of calcineurin-NFAT interaction
WO2019165183A1 (en) 2018-02-22 2019-08-29 Entrada Therapeutics, Inc. Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathy
WO2019217682A1 (en) 2018-05-09 2019-11-14 Ohio State Innovation Foundation Cyclic cell-penetrating peptides with one or more hydrophobic residues
CN114989254B (zh) * 2022-06-17 2023-11-03 中山大学 一种多肽及其设计方法和在制备抑制具核梭杆菌产品或预防结直肠癌药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60019318T2 (de) * 1999-09-22 2006-03-09 Canbas Co., Ltd., Numazu Zusammensetzungen und verfahren zur inhibierung vom zellulären g2-übergang und sensitisierung von zellen gegen dna-schädigenden wirkstoffe
WO2001094411A1 (en) 2000-06-05 2001-12-13 The Regents Of The University Of California Peptides modulating protease activated receptors and methods of using same
PT1483290E (pt) * 2002-01-17 2008-09-19 Takeda Pharmaceutical Peptídeos e peptidomiméticos possuindo actividade antiproliferativa e/ou que aumentam os agentes ou tratamentos de danificação dos ácidos nucleicos

Also Published As

Publication number Publication date
DE60322845D1 (de) 2008-09-25
EP1483290A2 (de) 2004-12-08
JP4041066B2 (ja) 2008-01-30
NO20043381L (no) 2004-10-12
AU2003235576C1 (en) 2009-12-10
PT1483290E (pt) 2008-09-19
JP2005529845A (ja) 2005-10-06
JP2011037896A (ja) 2011-02-24
KR100863090B1 (ko) 2008-10-13
WO2003059942A3 (en) 2004-10-07
CN1642978A (zh) 2005-07-20
AU2009201711B2 (en) 2011-12-15
HK1069179A1 (en) 2005-05-13
CN101092455A (zh) 2007-12-26
JP4873646B2 (ja) 2012-02-08
CN100360564C (zh) 2008-01-09
JP2008044946A (ja) 2008-02-28
DK1483290T3 (da) 2008-11-03
KR101103412B1 (ko) 2012-01-06
US20090253635A1 (en) 2009-10-08
CY1108470T1 (el) 2014-04-09
AU2009201711A1 (en) 2009-05-21
AU2003235576B2 (en) 2009-01-29
IL162836A0 (en) 2005-11-20
US7476657B2 (en) 2009-01-13
CA2471192C (en) 2014-05-20
US6995135B2 (en) 2006-02-07
CA2471192A1 (en) 2003-07-24
US20060084610A1 (en) 2006-04-20
US20040248783A1 (en) 2004-12-09
AU2003235576A1 (en) 2003-07-30
KR20080006649A (ko) 2008-01-16
NO332461B1 (no) 2012-09-24
IL162836A (en) 2011-09-27
WO2003059942A2 (en) 2003-07-24
EP1483290B1 (de) 2008-08-13
ES2311703T3 (es) 2009-02-16
KR20040081750A (ko) 2004-09-22
CN101092455B (zh) 2012-07-04
WO2003059942A9 (en) 2003-11-27
ZA200405455B (en) 2005-08-31
SI1483290T1 (sl) 2009-02-28

Similar Documents

Publication Publication Date Title
DE60322845D1 (de) Peptide und peptidmimetika mit anti-proliferativer aktivität und deren verwendung
BR0315688A (pt) Compostos, composições farmacêuticas e seus usos no tratamento ou prevenção de doenças ou condições de proliferação celular metabólicas
BRPI0411319A (pt) compostos terapeuticamente ativos e sua utilização
BRPI0513477A (pt) composições e processos de uso de proteìna 4 semelhante a angiotensina
TW200502385A (en) Modulation of forkhead box o1a expression
PT1955700E (pt) Tratamento terap?utico de doen?as associadas ao receptor de androg?nios
CY1110292T1 (el) Μεθοδοι για τη θεραπευτικη αντιμετωπιση αυτοανοσων νοσων με ενωσεις 2,4-πυριμιδινοδιαμινης
ECSP088425A (es) INHIBIDORES DE LA ACTIVIDAD Akt
BR0213786A (pt) Peptìdeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células
DE69533697D1 (de) ANTISENSE OLIGONUKLEOTIDMODULATION DER raf GENEXPRESSION
GB0225474D0 (en) Therapeutic agents
NO20003600D0 (no) Kaliumkanal inhibitorer
ATE324877T1 (de) Behandlung von metastatischer krankheit
EA200600424A1 (ru) Применение полипептидов семейства купредоксинов при лечении рака
MX2009008270A (es) Polipeptido novedoso que tiene actividad anti-tumoral.
ATE222119T1 (de) Verwendung von erythropoietin zur behandlung von multiple myelom
UA84954C2 (ru) Конденсированные пиримидоны, пригодные для лечения и профилактики злокачественного новообразования
DE60019318D1 (de) Zusammensetzungen und verfahren zur inhibierung vom zellulären g2-übergang und sensitisierung von zellen gegen dna-schädigenden wirkstoffe
NO994330L (no) Metode for behandling av en tumor
NO954880L (no) Cytidin deaminase
DE60143818D1 (de) Alpha-fetoprotein-peptide und ihre verwendung
DE69815840D1 (de) Verwendung von tall-104 zellen in kombination mit adriamyzin oder cisplatin zur behandlung von malignen tumoren
DE60229414D1 (de) Verwendung von aplidine in der behandlung von pankreaskrebs
DE69905392D1 (de) Verwendung von einer pharmazeutischen zusammensetzung enthaltende ein antikrebs mittel und mindestens ein peptid
DE59900286D1 (de) Verwendung von sphingosin-1-phosphat, sphingosin-1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1483290

Country of ref document: EP

EEIH Change in the person of patent owner